According to Stratistics MRC, the Global Insomnia market is expected to grow from $XX million in 2016 to reach $XX million by 2023 with a CAGR of XX%. Working in rational shifts & stressful work conditions, recent technological advancements and increasing demand for OTC sleep aids are some of the factors favoring the market growth. In addition, presence of large undiagnosed insomnia population pool and untapped markets in developing economies are the key opportunities for the market growth. On the contrary, side effects of benzodiazepine and non-benzodiazepine drugs, expiration of patients and increase in non pharmacological therapies are hindering the market growth.

Insomnia is a sleep disorder where in the person faces difficultly to sleep or remain asleep. The indications include depression, irritability, low stamina and daytime sleepiness. It is a highly predominant disorder that affects millions of people, globally. Insomnia-related conditions are caused due to disruption in circadian rhythm, chronic pain, hyperthyroidism, menopause, psychological stress, and other medical conditions. Furthermore, usage of drugs, such as alcohol, nicotine and caffeine will lead to insomnia.

In 2016, North America accounted for the highest market share in the insomnia market and is expected to maintain its dominance throughout the forecast period. In the U.S., the OTC treatment market is expected to hold a greater CAGR to address its growth in the insomnia pharmacological treatment. It is predicted to earn backing from the increasing utilization of melatonin valerian and roots, outstanding to their crucial advantages such as reduced stress levels and low side effects. Asia Pacific also appeared as a proper opportunity to capitalize on with the lifting disposable income and upsurge in the occurrence of chronic diseases.

Some of the key players in global insomnia market include Astellas, Biocodex S A, Consumer Healthcare Inc., Dainippon Sumitomo, ECR Pharmaceuticals, Eisai Co., Flynn Pharma, Johnson & Johnson, Meda Consumer Healthcare Inc., Merck & Co. Inc., Neurim, Pernix, Therapeutics, Pfizer Inc, Purdue Pharma L.P., Sanofi Pasteur, SkyePharma and Takeda Pharmaceutical Company.

Therapy Type Covered:
• Pharmacological Therapy
• Non-pharmacological Therapy
Disorder Durations Covered:
• Chronic Insomnia
• Transient Insomnia
• Acute Insomnia
Disorder Conditions Covered:
• Sleep onset and/or Maintenance
• Poor Quality of Sleep
• Other Disorder Condition
Formulation Types Covered:
• Capsules
• Tablets
• Oral mists

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements